Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors

Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors

Backgrounds In advanced pancreatic ductal adenocarcinoma (PDAC), immune therapy, including immune checkpoint inhibitors, has limited efficacy, encouraging the study of combination therapy.Methods Tumor necrosis factor receptor 2 (TNFR2) was analyzed via immunohistochemistry, immunofluorescence, west...

Full description

Bibliographic Details
Main Authors:	Yi Duan, Wen Chen, Jian Xu, Xiaozhen Zhang, Tingbo Liang, Xueli Bai, Mengyi Lao, Hanshen Yang, Muchun Li, Honggang Ying, Lihong He, Kang Sun, Chengxiang Guo, Haitao Jiang
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2022-03-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/10/3/e003982.full

Similar Items

Targeting TNFR2: A Novel Breakthrough in the Treatment of Cancer
by: Muchun Li, et al.
Published: (2022-04-01)

NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1
by: Xiaozhen Zhang, et al.
Published: (2021-07-01)

RCAN1-mediated calcineurin inhibition as a target for cancer therapy
by: Mengyi Lao, et al.
Published: (2022-06-01)

Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy
by: Xin Cui, et al.
Published: (2020-09-01)

Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy
by: Lingyue Liu, et al.
Published: (2022-02-01)

PD-1 immunotherapy in pancreatic cancer: current status
by: Ning Pu, MD, et al.
Published: (2019-03-01)

The Immunosuppressive Effect of TNFR2 Expression in the Colorectal Cancer Microenvironment
by: Nurul Hakimah Mohd Salim, et al.
Published: (2023-01-01)

Erzhi pills reverse PD-L1-mediated immunosuppression in melanoma microenvironment
by: Zhirui Fang, et al.
Published: (2024-02-01)

Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma
by: Huiyu Yan, et al.
Published: (2023-10-01)

Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1
by: Mukherjee, D, et al.
Published: (2023)

Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1
by: Debayan Mukherjee, et al.
Published: (2023-12-01)

Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression
by: Yunzhou Pu, et al.
Published: (2022-05-01)

Downregulation of Immunosuppressive Molecules, PD-1 and PD-L1 but not PD-L2, in the Patients with Multiple Sclerosis
by: Mohammad Reza Javan, et al.
Published: (2016-08-01)

The E3 ubiquitin ligases regulate PD-1/PD-L1 protein levels in tumor microenvironment to improve immunotherapy
by: Bo Hou, et al.
Published: (2023-01-01)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
by: Tingxuan Gu, et al.
Published: (2023-05-01)

Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma
by: Guilan Shi, et al.
Published: (2022-11-01)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021-09-01)

Reversing immunosuppression in the tumor microenvironment of fibrolamellar carcinoma via PD-1 and IL-10 blockade
by: S. K. Daniel, et al.
Published: (2024-03-01)

Cyclin G2 reverses immunosuppressive tumor microenvironment and potentiates PD-1 blockade in glioma
by: Sen Li, et al.
Published: (2021-08-01)

Apatinib remodels the immunosuppressive tumor ecosystem of gastric cancer enhancing anti-PD-1 immunotherapy
by: Qicong Luo, et al.
Published: (2023-05-01)

Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL
by: Tingting Zhang, et al.
Published: (2022-04-01)

Mechanism and Clinical Application of PD-1/PD-L1 Inhibitors in Immunotherapy
by: Yang Xicheng
Published: (2022-01-01)

Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
by: Laure Chardin, et al.
Published: (2021-12-01)

Elevation of spermine remodels immunosuppressive microenvironment through driving the modification of PD-L1 in hepatocellular carcinoma
by: Hong-Xiang Shi, et al.
Published: (2022-11-01)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
by: Ana Bocanegra, et al.
Published: (2020-08-01)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
by: Nicholas J. Bevins, et al.
Published: (2022-11-01)

Drug-loaded microbubble delivery system to enhance PD-L1 blockade immunotherapy with remodeling immune microenvironment
by: Jun Zheng, et al.
Published: (2023-02-01)

Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment
by: Simeng Wang, et al.
Published: (2021-10-01)

Sequential delivery of PD-1/PD-L1 blockade peptide and IDO inhibitor for immunosuppressive microenvironment remodeling via an MMP-2 responsive dual-targeting liposome
by: Chuan Hu, et al.
Published: (2023-05-01)

Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy
by: Enliang Li, et al.
Published: (2021-09-01)

Identification and validation of stromal-tumor microenvironment-based subtypes tightly associated with PD-1/PD-L1 immunotherapy and outcomes in patients with gastric cancer
by: Qianqian Ren, et al.
Published: (2020-03-01)

PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy
by: Xiaohui Ren, et al.
Published: (2024-04-01)

An extension of cancer immunotherapy with dostarlimab, the PD1-PD L1 pathway blocker
by: Sitangshu Sekhar Biswas, et al.
Published: (2023-12-01)

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
by: David Escors, et al.
Published: (2022-10-01)

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019-05-01)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
by: Qian Li, et al.
Published: (2022-12-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01)

New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1
by: Nicolas Villanueva, et al.
Published: (2018-09-01)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
by: Xin Wang, et al.
Published: (2019-02-01)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
by: Bogang Wu, et al.
Published: (2018-11-01)